Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

Endocrine-Related Cancer

Volumn 18, Issue 6, 2011, Pages 657-668

  Lamers, Fieke ^a   Van Der Ploeg, Ida ^a   Schild, Linda ^a   Ebus, Marli E ^a   Koster, Jan ^a   Hansen, Bo R ^b   Koch, Troels ^b   Versteeg, Rogier ^a   Caron, Huib N ^a   Molenaar, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Santaris Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 2; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53; SURVIVIN;

ADRENAL MEDULLA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHROMOSOME 17Q; CONTROLLED STUDY; DISASTER; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; NEUROBLAST; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROGNOSIS; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 2; CASPASE INHIBITORS; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MITOSIS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855957229     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0207     Document Type: Article

References (46)

1. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M & Altieri DC 1998 Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351 882-883. (doi:10.1016/S0140-6736(05)70294-4)
2. Altieri DC 2003 Validating survivin as a cancer therapeutic target. Nature Reviews. Cancer 3 46-54. (doi:10.1038/nrc968)
3. Altieri DC 2006 The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Current Opinion in Cell Biology 18 609-615. (doi:10.1016/j.ceb.2006.08.015)
4. Altieri DC 2008 Opinion - survivin, cancer networks and pathway-directed drug discovery. Nature Reviews. Cancer 8 61-70. (doi:10.1038/nrc2293)
5. Basu A, Adkins B & Basu C 2008 Down-regulation of caspase-2 by rottlerin via protein kinase c-delta-independent pathway. Cancer Research 68 2795-2802. (doi:10.1158/0008-5472.CAN-07-6244)
6. Beane RL, Ram R, Gabillet S, Arar K, Monia BP & Corey DR 2007 Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. Biochemistry 46 7572-7580. (doi:10.1021/bi700227g)
7. Caldas H, Honsey LE & Altura RA 2005 Survivin 2 alpha: a novel survivin splice variant expressed in human malignancies. Molecular Cancer 4 11. (doi:10.1186/1476-4598-4-11)
8. Castedo M, Perfettini JL, Roumie T, Andreau K, Medema R & Kroemer G 2004a Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 2825-2837. (doi:10.1038/sj.onc.1207528)
9. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, Horne D, Feunteun J, Lenoir G, Medema R et al. 2004b Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 23 4362-4370. (doi:10.1038/sj.onc.1207572)
10. Chou TC & Talalay P 1984 Quantitative-analysis of dose-effect relationships - the combined effects of multiple-drugs or enzyme-inhibitors. Advances in Enzyme Regulation 22 27-55. (doi:10.1016/0065-2571(84)90007-4)
11. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M et al. 2006 Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biology 7 R84. (doi:10.1186/gb-2006-7-9-r84)
12. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S et al. 2004 An IAP-IAP complex inhibits apoptosis. Journal of Biological Chemistry 279 34087-34090. (doi:10.1074/jbc.C400236200)
13. Fangusaro JR, Caldas H, Jiang YY & Altura RA 2006 Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatric Blood & Cancer 47 4-13. (doi:10.1002/pbc.20805)
14. Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS et al. 2009 Survivin minigene DNA vaccination is effective against neuroblastoma. International Journal of Cancer 125 104-114. (doi:10.1002/ijc.24291)
15. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, Delattre O & Janoueix-Lerosey I 2008 Characterization of amplicons in neuroblastoma: highresolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes, Chromosomes & Cancer 47 819-834. (doi:10.1002/gcc.20583)
16. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A & Shamsili S 2009 Multicenter phase ii trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. Journal of Clinical Oncology 27 4481-4486. (doi:10.1200/JCO.2008.21.1862)
17. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, Rosenbohm C, Wissenbach M, Orum H & Koch T 2008 SPC3042: a proapoptotic survivin inhibitor. Molecular Cancer Therapeutics 7 2736-2745. (doi:10.1158/1535-7163.MCT-08-0161)
18. Henry MCW, Tashjian DB & Breuer CK 2005 Neuroblastoma update. Current Opinion in Oncology 17 19-23. (doi:10.1097/01.cco.0000147901.12325.90)
19. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y et al. 2000 High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 617-623. (doi:10.1038/sj.onc.1203358)
20. Jiang YY, Saavedra HI, Holloway MP, Leone G & Altura RA 2004 Aberrant regulation of survivin by the RB/E2F family of proteins. Journal of Biological Chemistry 279 40511-40520. (doi:10.1074/jbc.M404496200)
21. Lens SMA, Wolthuis RMF, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G & Medema RH 2003 Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO Journal 22 2934-2947. (doi:10.1093/emboj/cdg307)
22. Lens SMA, Rodriguez JA, Vader G, Span SW, Giaccone G & Medema RH 2006 Uncoupling the central spindleassociated function of the chromosomal passenger complex from its role at centromeres. Molecular Biology of the Cell 17 1897-1909. (doi:10.1091/mbc.E05-08-0727)
23. Maris JM, Hogarty MD, Bagatell R & Cohn SL 2007 Neuroblastoma. Lancet 369 2106-2120. (doi:10.1016/S0140-6736(07)60983-0)
24. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I & Reed JC 2003 HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO Journal 22 2729-2740. (doi:10.1093/emboj/cdg263)
25. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R & Caron HN 2008 Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Research 68 2599-2609. (doi:10.1158/0008-5472.CAN-07-5032)
26. Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN et al. 2011 Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes a poor prognosis. Genes Chromosomes and Cancer [in press].
27. Mook OR, Baas F, de Wissel MB & Fluiter K 2007 Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Molecular Cancer Therapeutics 6 833-843. (doi:10.1158/1535-7163.MCT-06-0195)
28. Muhlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM & Gross N 2008 Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Molecular Cancer 7 55. (doi:10.1186/1476-4598-7-55)
29. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M et al. 2007 YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Research 67 8014-8021. (doi:10.1158/0008-5472.CAN-07-1343)
30. van Noesel MM & Versteeg R 2004 Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre'. Gene 325 1-15. (doi:10.1016/j.gene.2003.09.042)
31. Nutt LK, Margolis SS, Jensen M, Herman CE, Dunphy WG, Rathmell JC & Kornbluth S 2005 Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell 123 89-103. (doi:10.1016/j.cell.2005.07.032)
32. Petersen M & Wengel J 2003 LNA: a versatile tool for therapeutics and genomics. Trends in Biotechnology 21 74-81. (doi:10.1016/S0167-7799(02)00038-0)
33. Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC & Schönthal AH 2006 Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Molecular Cancer 5 19. (doi:10.1186/1476-4598-5-19)
34. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang LL, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT et al. 2003 A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics 33 401-406. (doi:10.1038/ng1117)
35. Ruchaud S, Carmena M & Earnshaw WC 2007 The chromosomal passenger complex: one for all and all for one. Cell 131 230-231. (doi:10.1016/j.cell. 2007.10.002)
36. Ryan BM, O'Donovan N & Duffy MJ 2009 Survivin: a new target for anti-cancer therapy. Cancer Treatment Reviews 35 553-562. (doi:10.1016/j.ctrv. 2009.05.003)
37. Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM & Horak ID 2010 Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides, Nucleotides & Nucleic Acids 29 97-112. (doi:10.1080/15257771003597733)
38. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y et al. 2009 Phase I study of YM155, a novel survivinsuppressant, in patients with advanced solid tumors. Clinical Cancer Research 15 3872-3880. (doi:10.1158/1078-0432.CCR-08-1946)
39. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S & Shafit-Zagardo B 2001 Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. Journal of Neurochemistry 79 426-436. (doi:10.1046/j.1471-4159.2001.00596.x)
40. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B & Wiman KG 2008 PRIMA-1(MET) induces mitochondrial apoptosis through activation of caspase-2. Oncogene 27 6571-6580. (doi:10.1038/onc.2008.249)
41. Song ZY, Yao XB & Wu M 2003 Direct interaction between survivin and Smac/DIABLO is essential for the antiapoptotic activity of survivin during taxol-induced apoptosis. Journal of Biological Chemistry 278 23130-23140. (doi:10.1074/jbc.M300957200)
42. Tinnikov AA, Yeung KT, Das S & Samuels HH 2009 Identification of a novel pathway that selectively modulates apoptosis of breast cancer cells. Cancer Research 69 1375-1382. (doi:10.1158/0008-5472.CAN-08-2896)
43. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P et al. 2008 Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. Journal of Clinical Oncology 26 5198-5203. (doi:10.1200/JCO.2008.17.2064)
44. Vester B & Wengel J 2004 LNA (Locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43 13233-13241. (doi:10.1021/bi0485732)
45. Wheatley SP & McNeish A 2005 Survivin: a protein with dual roles in mitosis and apoptosis. International Review of Cytology: A Survey of Cell Biology 247 35-88. (doi:10.1016/S0074-7696(05)47002-3)
46. Zangemeister-Wittke U & Simon HU 2004 An IAP in action - the multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 3 1121-1123. (doi:10.4161/cc.3.9.1093)